Evidence map›Paper›PMID 33083279›Full record

ArticleLiver cancer2020

Dietary Restriction Suppresses Steatosis-Associated Hepatic Tumorigenesis in Hepatitis C Virus Core Gene Transgenic Mice.

Fangping Jia, Pan Diao, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Makoto Nakamuta, Ibuki Nakamura, Saki Shirotori, Yoshiko Sato, Kyoji Moriya and 5 more

Open access · goldAbstract read
In one paragraph

Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Fangping JiaDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Pan DiaoDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Xiaojing WangDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Xiao HuDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Takefumi KimuraDepartment of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
Makoto NakamutaDepartment of Gastroenterology, Kyushu Medical Center, Fukuoka, Japan.
Ibuki NakamuraDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Saki ShirotoriDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Yoshiko SatoDepartment of Molecular Pathology, Shinshu University School of Medicine, Matsumoto, Japan.
Kyoji MoriyaDepartment of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan.
Kazuhiko KoikeDepartment of Gastroenterology, The University of Tokyo, Tokyo, Japan.
Frank J GonzalezLaboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jun NakayamaDepartment of Molecular Pathology, Shinshu University School of Medicine, Matsumoto, Japan.
Toshifumi AoyamaDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Naoki TanakaDepartment of Metabolic Regulation, Shinshu University School of Medicine, Matsumoto, Japan.
Shinshu University · JPHebei Medical University · CNNational Institutes of Health · USNational Kyushu Medical Center · JPThe University of Tokyo · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsDietary restriction (DR) is a preventive strategy for obesity, metabolic syndrome, cardiovascular disease, and diabetes. Although an interconnection between obesity, metabolic syndrome, fatty liver, and hepatocellular carcinoma has been documented, the mechanism and impact of DR on steatosis-derived hepatocarcinogenesis are not fully understood. This study aimed to evaluate whether DR can prevent hepatic tumorigenesis.

methodsMale hepatitis C virus core gene transgenic (HCVcpTg) mice that develop spontaneous age-dependent insulin resistance, hepatic steatosis, and ensuing liver tumor development without apparent hepatic fibrosis, were fed with either a control diet ad libitum (control group) or 70% of the same control diet (DR group) for 15 months, and liver phenotypes were investigated.

resultsDR significantly reduced the number and volume of liver tumors. DR attenuated hepatic oxidative and endoplasmic reticulum stress and markedly suppressed nuclear factor-κB, signal transducer and activator of transcription 3 (STAT3) and STAT5, and phosphorylation of extracellular signal-regulated kinase, leading to downregulation of several pro-oncogenic mediators, such as cyclin D1. Serum insulin and insulin-like growth factor 1 levels, as well as hepatic expression of insulin receptor substrate 1/2, phosphatidylinositol-3 kinase, and serine/threonine-protein kinase AKT, were downregulated by DR. A transcriptome analysis revealed that STAT3 signaling and lipogenesis were the most suppressed hepatocarcinogenic pathways affected by DR. Additionally, DR stimulated autophagy and p62/sequestosome 1 degradation, enhanced phosphorylation of AMP-activated protein kinase α, increased fibroblast growth factor 21 expression, and attenuated expression of senescence-associated secretory phenotypes.

conclusionDR suppressed steatosis-associated hepatic tumorigenesis in HCVcpTg mice, mainly due to attenuation of pathways involved in inflammation, cellular stress, cell proliferation, insulin signaling, and senescence. These findings support the notion that persistent 30% reduction of daily food intake is beneficial for preventing steatosis-associated hepatocarcinogenesis caused by HCV core protein.

Indexed as

Cyclin D1NF-κBp62/SQSTM1SenescenceSTAT3

Identifiers

PMID33083279
PMCPMC7548900
OpenAlexW3041927033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.